Cantor Fitzgerald Increases Earnings Estimates for SI-BONE

SI-BONE, Inc. (NASDAQ:SIBN - Free Report) - Analysts at Cantor Fitzgerald increased their FY2024 earnings per share estimates for SI-BONE in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.69) per share for the year, up from their previous estimate of ($0.95). The consensus estimate for SI-BONE's current full-year earnings is ($0.78) per share.

Several other equities research analysts also recently weighed in on SIBN. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 target price on shares of SI-BONE in a research report on Wednesday, November 13th. Morgan Stanley reduced their price target on SI-BONE from $21.00 to $19.00 and set an "overweight" rating for the company in a report on Tuesday, August 6th. Finally, Truist Financial increased their price target on SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $23.00.

SI-BONE Trading Down 2.6 %

SI-BONE stock traded down $0.34 during trading on Monday, hitting $12.58. The company's stock had a trading volume of 152,249 shares, compared to its average volume of 391,264. The stock has a market capitalization of $527.58 million, a price-to-earnings ratio of -14.04 and a beta of 1.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 8.25. The stock's fifty day moving average is $14.03 and its 200 day moving average is $14.29. SI-BONE has a 1-year low of $11.76 and a 1-year high of $21.70.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in SI-BONE by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company's stock worth $40,328,000 after purchasing an additional 43,670 shares during the last quarter. Champlain Investment Partners LLC raised its position in shares of SI-BONE by 104.8% during the 1st quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company's stock valued at $40,158,000 after acquiring an additional 1,255,610 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of SI-BONE by 79.8% in the 1st quarter. Bessemer Group Inc. now owns 37,859 shares of the company's stock valued at $620,000 after buying an additional 16,800 shares during the period. EntryPoint Capital LLC grew its holdings in shares of SI-BONE by 78.4% in the 1st quarter. EntryPoint Capital LLC now owns 13,906 shares of the company's stock valued at $228,000 after buying an additional 6,113 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of SI-BONE by 7.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company's stock valued at $336,000 after buying an additional 1,372 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at SI-BONE

In other news, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at approximately $3,169,734.96. The trade was a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 5,060 shares of company stock worth $72,621 over the last three months. Corporate insiders own 3.90% of the company's stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.